Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after UCART19 exposure
2026-526212-37-00Phase 3Authorised
- Sponsor
- Servier
- Start
- Jun 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of UCART19 in lymphoid leukemia, sponsored by Servier. Primary endpoints: Adverse events within 12 months after last infusion, Adverse events of special interest and 2 more. Planned start Jun 2026; status: authorised.
02
Drugs
UCART19
03
Conditions
lymphoid leukemia
Beyond the preview
Go deeper on 2026-526212-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526212-37-00.